Advertisement

Topics

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

07:30 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application ...

Other Sources for this Article

Kalytera Therapeutics, Inc.
Robert Farrell, 888-861-2008
President, CEO
info@kalytera.co

NEXT ARTICLE

More From BioPortfolio on "Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...